A mobile, self-contained system for enhancing plant growth comprising: a mobile structure comprising a plurality of wheels so that the system can be moved; a vessel supported by the structure; a recirculating pump supported by the structure and exterior to the vessel, the pump having a first discharge line and a second discharge line; a generator supported by the structure; a vessel outlet from a bottom portion of the vessel to the pump; and an aerator for injecting air into the first discharge line; wherein the first discharge line extends from the pump directly into the bottom portion of the vessel, such that the contents of the vessel can be recirculated by the pump from the vessel outlet back into the vessel through the first discharge line and the second discharge line extends from the pump and is adapted for discharging contents of the vessel directly into an irrigation system.

The present invention relates to the isolated strain of Lactobacillus plantarum VF46A deposited at the CNCM (Collection Nationale De Cultures de Microorganismes, INSTITUT PASTEUR, 25 rue du Docteur Roux, F-75724 PARIS CEDEX15) under the number CNCM 1-5301 on 29 Mar. 2018 as well as to a pharmaceutical composition, a food supplement and a food comprising said strain.

The present invention relates to the isolated strain of Lactobacillus plantarum VF46A deposited at the CNCM (Collection Nationale De Cultures de Microorganismes, INSTITUT PASTEUR, 25 rue du Docteur Roux, F-75724 PARIS CEDEX15) under the number CNCM 1-5301 on 29 Mar. 2018 as well as to a pharmaceutical composition, a food supplement and a food comprising said strain.

The invention belongs to the field of cosmetic biotechnology, and specifically relates to an Enterobacter that degrades hyaluronic acid and a cultivation method and application thereof. The Enterobacter sp. CGJ001 of the present invention was deposited in the China General Microbiological Culture Collection Center on Oct. 10, 2019, and the preservation number is CGMCC NO. 18661. The Enterobacter strain can efficiently produce hyaluronidase, and can be used in the process of preparing low molecular hyaluronic acid and oligomeric hyaluronic acid from high molecular hyaluronic acid. The enzyme has high specificity towards hyaluronic acid, excellent thermal stability and pH stability, and is suitable for large-scale industrial application. Thus, it can replace the traditional hyaluronidase extracted from expensive animal tissues. There should be broad application prospects in the fields of medicine and cosmetics.

The invention belongs to the field of cosmetic biotechnology, and specifically relates to an Enterobacter that degrades hyaluronic acid and a cultivation method and application thereof. The Enterobacter sp. CGJ001 of the present invention was deposited in the China General Microbiological Culture Collection Center on Oct. 10, 2019, and the preservation number is CGMCC NO. 18661. The Enterobacter strain can efficiently produce hyaluronidase, and can be used in the process of preparing low molecular hyaluronic acid and oligomeric hyaluronic acid from high molecular hyaluronic acid. The enzyme has high specificity towards hyaluronic acid, excellent thermal stability and pH stability, and is suitable for large-scale industrial application. Thus, it can replace the traditional hyaluronidase extracted from expensive animal tissues. There should be broad application prospects in the fields of medicine and cosmetics.

The present invention relates to two new strains of lactic acid bacteria, Lactobacillus brevis DSM 33325 and Lactobacillus plantarum DSM 33326, to a new food composition, and to the process for the preparation thereof.

The present invention provides a prophylactic or therapeutic composition for graft-versus-host disease (GVHD).

There is provided a prophylactic or therapeutic composition for GVHD, which comprises bacteria belonging to any genus selected from the group consisting of the following genera: Blautia, Clostridium, unclassified Clostridiales, Actinomyces, Parabacteroides, Lachnoclostridium, Bacteroides, Faecalibacterium, unclassified Lachnospiraceae, Roseburia, Ruminococcus, unclassified Firmicutes, Dorea, Phascolarctobacterium, Sutterella, Megamonas, Collinsella, Eubacterium, and Coprococcus, etc., or any combination of bacteria belonging to these genera.

Conventional methods for treating fat, oil, grease (FOG) and other build-up in wastewater systems (including grease traps) of restaurants and the like typically rely on chemical-based detergents, which may be damaging both to the environment and to the wastewater system itself. While some bio-friendly alternatives are known, a common problem with all these agents is that they are “flushed through” the system rapidly, and thus are relatively ineffective and inefficient. In providing an onsite system and method comprising cultivating micro-organisms and then using a carrier to deliver them to an affected environment, the present invention provides a solution that is more efficient in requiring less “starter” ingredients as well as more effective in ensuring the cultivated micro-organisms are delivered to, maintain sustained contact with, and have adequate time to treat, the undesirable substance(s).

The present disclosure relates to a strain of Lactobacillus sakei HEM224 (KCTC14065BP) and a composition for treating, preventing or alleviating inflammation or asthma, comprising the strain.

A strain of Lactobacillus sakei HEM224 (KCTC14065BP) according to an embodiment of the present disclosure inhibits the production of pro-inflammatory factors or inflammatory factors, and exhibits an effect of treating asthma in an asthma animal model. Therefore, the strain can be applied to pharmaceutical compositions, food compositions, health functional food compositions and feed compositions for treating, preventing or alleviating inflammation or asthma.

The present disclosure relates to a strain of Lactobacillus sakei HEM224 (KCTC14065BP) and a composition for treating, preventing or alleviating inflammation or asthma, comprising the strain.

A strain of Lactobacillus sakei HEM224 (KCTC14065BP) according to an embodiment of the present disclosure inhibits the production of pro-inflammatory factors or inflammatory factors, and exhibits an effect of treating asthma in an asthma animal model. Therefore, the strain can be applied to pharmaceutical compositions, food compositions, health functional food compositions and feed compositions for treating, preventing or alleviating inflammation or asthma.